Drug Profile
Daridorexant - Idorsia Pharmaceuticals
Alternative Names: ACT 541468; Daridorexant hydrochloride - Idorsia Pharmaceuticals; DORA; Nemorexant - Idorsia Pharmaceuticals; QUVIVIQLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals; Simcere Pharmaceutical Group
- Class Benzimidazoles; Chlorinated hydrocarbons; Ketones; Pyrrolidines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Insomnia
- No development reported Sleep apnoea syndrome
Most Recent Events
- 05 Feb 2024 Jiangsu Simcere Pharmaceutical completes a phase I pharmacokinetic trial (In volunteers) in China (PO, Tablet) (NCT06326723)
- 10 Jan 2024 Launched for Insomnia in Canada, United Kingdom, Spain (PO)
- 01 Nov 2023 Mochida enters into a marketing agreement with Shionogi to market daridorexant in Japan